GENE ONLINE|News &
Opinion
Blog

China NMPA
AstraZeneca’s Treatment for Chronic Kidney Disease Wins Yet Another Approval
2022-09-05
Lepu, HanX Scores China Approval For PD-1 Inhibitor
2022-07-27
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
Innovent’s PCSK-9 Antibody Meets Primary Endpoints in Two Phase 3 Studies
2022-02-18
China Gives Conditional Approval to Pfizer’s Covid-19 Oral Antiviral
2022-02-14
GSK’s Benlysta Bags Approval for Lupus Nephritis Treatment in China
2022-02-14
China’s CANbridge Reports Positive Phase 1 Data of Contender to AstraZeneca’s Complement Inhibitor
2022-02-08
Antengene’s XPO1 Inhibitor Receives First-In-Class Approval in China for Multiple Myeloma
2021-12-20
Brii Bio’s COVID-19 Antibody Cocktail Gets the Greenlight in China
2021-12-09
JW Therapeutics’ CAR-T Approval in China Comes On the Heels of its Rival
2021-09-08
Chinese Regulator Accepts BeiGene’s Tislelizumab sBLA for Nasopharyngeal Cancer
2021-08-23
Gilead’s Yescarta Becomes First CAR-T Therapy to Score Regulatory Approval in China
2021-06-27
Innovent, Lilly Bag Third Approval for PD-1 Inhibitor Tyvyt in China
2021-06-07
Forxiga Gains Approval in China for Multiple Cardio-Related Diseases
2021-02-07
BeiGene’s Immunotherapy Drug Shines in Phase ESCC Trial
2021-01-31
1 2 3
LATEST
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top